About US
Contact us
-
Amarin wins injunction against FDA in free speech caseOn Friday, Amarin ($AMRN) won what was being called a First Amendment free speech victory for drugmakers. It got a federal court to say the FDA cannot bar Amarin from discussing off-label use of its f2015/8/10
-
Short-sellers target Bavarian Nordic and its cancer vaccine candidateAs it works to bring its prostatecancer vaccineProstvac to market and expand its smallpox vaccine business, Danish vaccine makerBavarian Nordic encountered a new set of challenges this week. Despite a2015/8/7
-
Mylan CEO Bresch: We want Perrigo--but we don't need itPerrigo CEO Joseph Papa said this week that he doesn't intend to make it easy for Mylan to pull off a hostile takeover of his company. But the way Mylan sees it, if it loses out, it's not the end of t2015/8/7
-
Novo Nordisk launches diabetes 'dream team' contest with NBA star as a prizeFormer NBA star Dominique Wilkins is not just a spokesman for Novo Nordisk's ($NVO)Victoza. He's also a prize in a Type 2 diabetes sweepstakes the drugmaker is rolling out. Through the company's "Diab2015/8/6
-
With $300M spent on potential split, Pfizer CEO now 'biased' toward branded M&ANow that Hospira's ($HSP) in the bag, Pfizer ($PFE) execs have less of an appetite for M&A in their Established Products unit. That $16 billion deal gives Pfizer added heft in injectable generics,2015/8/6
-
DME data helps Eylea soar in Q2--and poach market share from its Roche rivalsEarlier this year, Regeneron ($REGN) scored a win when its eye drugEyleaoutperformed a pair of Roche ($RHHBY) meds in a head-to-head study. And now, that win is paying off. Revenue doubled for the Ta2015/8/5
-
Baxalta to Shire: We're young, we're just starting to grow, and we're rejecting your buyout offerTuesday, Shire went public with a $30 billion bid for Baxalta that had already been rejected once. And the second time around, Baxalta had the same answer: It's not happening. Shire's $45.23-per-shar2015/8/5
-
UPDATED: India's Wockhardt recalls millions of packages of drugs in sweeping recallWhen India'sWockhardtacknowledged recently it was pulling all of the drugs still on the market that it had shipped before theFDAbanned two of its plants, it didn't say what those numbers might add up2015/8/4
-
Surprise! It's a DTC campaign for Sanofi and MannKind's AfrezzaThere's been lots of hullaballoo surrounding Sanofi ($SNY) and MannKind's ($MNKD) launch of inhaled insulinAfrezza, but for the arrival of the pair's first DTC campaign? Not so much. The companies rec2015/8/4
-
CEO Bradway, and markets, like the way Amgen's 'new product story' is shaping upAmgen ($AMGN) is only weeks away from an anticipatedFDAapproval for itsPCSK9cholesterol reducer. Already approved in Europe, the drug is expected to quickly reap blockbuster sales. As Amgen's "new pro2015/8/3